Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Global Partners LP

    NYSE: GLP · Real-Time Price · USD
    51.52
    -1.69 (-3.18%)
    At close: Jun 25, 2025, 3:59 PM
    51.07
    -0.86%
    After-hours: Jun 25, 2025, 05:52 PM EDT
    -3.18%
    Bid 51
    Market Cap 1.75B
    Revenue (ttm) 21.75B
    Net Income (ttm) 131.98M
    EPS (ttm) 3.14
    PE Ratio (ttm) 16.41
    Forward PE 17.64
    Analyst Hold
    Ask 53
    Volume 37,489
    Avg. Volume (20D) 57,024
    Open 53.41
    Previous Close 53.21
    Day's Range 51.35 - 53.76
    52-Week Range 37.00 - 60.00
    Beta 1.02

    About GLP

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GLP
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GLP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    news image

    5 days ago · reuters.com

    China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds

    Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a simila...

    news image

    4 days ago · seekingalpha.com

    Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play

    NVO's bottom has finally materialized after the painful halving from June 2024 peaks, as the GLP-1 compounding/supply headwinds moderate. This is significantly aided by the expanded partnership with n...

    news image

    1 week ago · fool.com

    Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

    Eli Lilly (LLY -0.41%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients w...

    news image

    1 week ago · businesswire.com

    Global Partners LP Announces Expiration and Results of Its Cash Tender Offer for Any and All of Its Outstanding 7.00% Senior Notes Due 2027

    WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) announced today that the cash tender offer (the “Offer”) commenced on June 10, 2025 to purchase any and all of the outstandin...

    news image

    1 week ago · zacks.com

    Global Partners (GLP), a Top Stock to Buy Amid the Spike in Oil Prices

    Operating one of the largest terminal networks of refined petroleum products in the Northeastern United States, Global Partners (GLP) is an appealing stock to consider amid the sharp spike in crude oi...

    news image

    1 week ago · businesswire.com

    Global Partners LP Announces Pricing Terms of Cash Tender Offer for Any and All Outstanding 7.00% Senior Notes Due 2027

    WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) announced today the pricing terms of the previously announced cash tender offer (the “offer”) to purchase any and all of the ...

    news image

    1 week ago · accessnewswire.com

    Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

    SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump...

    news image

    1 week ago · seekingalpha.com

    The 9.2% Yield Of The Preferred Stock Of Global Partners Is Highly Attractive

    Global Partners' preferred stock offers a 9.2% yield with strong dividend safety, appealing to income-focused and conservative investors amid market volatility. The company demonstrates resilience to ...

    news image

    2 weeks ago · businesswire.com

    AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

    AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonst...

    news image

    2 weeks ago · accessnewswire.com

    Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

    Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R))  Lexaria has now demonstrated, in distinct human clinical studies,...

    Add to Watchlist